Arbutus Biopharma Sues Pfizer, BioNTech Over Alleged Patent Infringement -- Update
04 Abril 2023 - 10:18AM
Dow Jones News
By Will Feuer
Arbutus Biopharma Corp. and its licensee Genevant Sciences have
filed a patent-infringement lawsuit against Pfizer Inc. and
BioNTech SE related to the latter's Covid-19 vaccine.
Arbutus Biopharma, a clinical-stage biopharmaceutical company,
said Tuesday that the patents relate to nucleic acid-lipid
particles and their composition, manufacture, delivery and methods
of use.
The company said Genevant is seeking compensation for Pfizer's
and BioNTech's unlicensed use of its patented lipid nanoparticle
delivery technologies in their Covid-19 vaccine.
"We believe that Pfizer and BioNTech could not have created and
manufactured effective vaccines at such an unprecedented speed
without the existing, proven and patented LNP technologies owned by
Arbutus and licensed to Genevant," Arbutus Biopharma Chief
Executive William Collier said.
Representatives for BioNTech didn't immediately return a request
for comment.
Pfizer said in a statement that it hadn't yet received the
complaint. "However, we remain confident in our intellectual
property supporting the Pfizer/BioNTech vaccine and will vigorously
defend against the allegations of the lawsuit," the company
said.
Shares of Arbutus Biopharma slipped by about 1% to $3.03 a share
in premarket trading.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
April 04, 2023 09:03 ET (13:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024